Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 2, 2000, Pages 108-114

  Becerra, Mercedes C ^a,b   Freeman, J ^a   Bayona, J ^a,b   Shin, S S ^a,b   Kim, J Y ^a,b   Furin, J J ^a,b   Werner, B ^a   Sloutsky, A ^a   Timperi, R ^a   Wilson, M E ^a   Pagano, M ^a   Farmer, P E ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Directly observed therapy; DOTS Plus; Multidrug resistance; Peru; Treatment failure; Tuberculosis

Indexed keywords

CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PERU; RISK ASSESSMENT; SAMPLING STUDIES; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0034100360     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Pan American Health Organization-Peru; World Health Organization; Ministerio de Salud-Peru. Report of a review of the National Tuberculosis Control Programme: Peru. Washington, DC: PAHO, March 1994.
2. Ministerio de Salud. Tuberculosis en el Peru - Informe 1997. Lima, Peru: Ministerio de Salud, 1998.
3. Webb R; Fernandez-Baca G. Perú en numéros 1997: anuario estadístico. Lima, Peru: Cuanto SA, 1997.
4. Ministerio de Salud. Programa Nacional de Control de la Tuberculosis en el Perú: Año 1994. Lima, Peru: Ministerio de Salud, 1995.
5. Sanghavi D M, Gilman R H, Lescano-Guevara A G, Checkley W, Cabrera L Z, Cardenas V. Hyperendemic pulmonary tuberculosis in a Peruvian shantytown. Am J Epidemiol 1998; 148: 384-389.
6. Getchell W S, Davis C E, Gilman J, Urueta G, Ruiz-Huidobro E, Gilman R H. Basic epidemiology of tuberculosis in Peru: a prevalence study of tuberculin sensitivity in a pueblo joven. Am J Trop Med Hyg 1992; 47: 721-729.
7. Madico G, Gilman R H, Checkley W, et al. Community infection ratio as an indicator for tuberculosis control. Lancet 1995; 345: 416-419.
8. Ministerio de Salud. Tuberculosis en el Perú - Informe 1996. Lima, Peru: Ministerio de Salud, 1997.
9. Suarez P G, Jave O, Canales R, Portocarrero J, Alarcon E. Who, when, where and why tuberculosis patients die during short course treatment. Tubercle Lung Dis 1996; 77 (Suppl 2): 73.
10. World Health Organization. WHO Report on the Tuberculosis Epidemic. WHO/TB/97.224. Geneva: World Health Organization, 1997.
11. World Health Organization. Treatment of tuberculosis: Guidelines for National Programmes. Geneva, Switzerland: World Health Organization, 1996.
12. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 122 842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
13. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
14. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/TB/ 97.229. Geneva: World Health Organization; 1997.
15. Laszlo A, de Kantor I N. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ 1994; 72: 603-610.
16. Asencios L, Sanabria H, Diaz S, Quispe N. Resistencia inicial de M. tuberculosis a las drogas antituberculosas (1988-1989). Rev Med Hered 1993; 4: 62-66.
17. World Health Organization. WHO Tuberculosis Programme: Framework for effective tuberculosis control. WHO/TB/ 94.175. Geneva: World Health Organization; 1994.
18. Farmer P E, Bayona J, Shin S, et al. Preliminary results of community-based MDRTB treatment in Lima, Peru. Int J Tuberc Lung Dis 1998; 2 (Suppl 2): S371.
19. Haas D W, Des Prez R M. Mycobacterium tuberculosis. In: Mandell G L, Bennett J E, Dolin R, eds. Principles and practice of infectious diseases. Fourth ed. New York: Churchill Livingstone, 1995: pp 2213-2243.
20. Smithwick R W. Laboratory manual for acid-fast microscopy. Second ed. Atlanta, GA: CDC, 1976.
21. Strong B E, Kubica G. Isolation and identification of Mycobacterium tuberculosis: a guide for the Level II Laboratory. Atlanta, GA: Centers for Disease Control, 1981.
22. Kent P T, Kubica G. Public Health Mycobacteriology. A Guide for the Level III Laboratory. Atlanta, GA: DHHS, Centers for Disease Control, 1985.
23. Hawkins J E. Non weekend schedule for BACTEC drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 1986; 23: 934-937.
24. Pagano M, Gauvreau K. Principles of biostatistics. Belmont, CA: Duxbury Press, 1993.
25. Fischl M A, Uttamchandani R B, Daikos G L, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117: 177-183.
26. Friedman C F, Stoeckle M Y, Kreiswirth B N, et al. Transmission of multidrug-resistant tuberculosis in a large urban setting. Am J Respir Crit Care Med 1995; 152: 355-359.
27. Neher A, Breyer G, Shrestha B, Feldmann K. Directly observed intermittent short-course chemotherapy in the Kathmandu valley. Tubercle Lung Dis 1996; 77: 302-307.
28. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment tuberculosis cases: Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
29. Fodor T, Vadász I, Lõrinczi I. Drug-resistant tuberculosis in Budapest. Int J Tuberc Lung Dis 1998; 2: 732-735.
30. Coninx R, Pfyffer G E, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. Brit Med J 1998; 316: 1423-1425.
31. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353: 969-973.
32. Kimerling M E, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDRTB. Int J Tuberc Lung Dis 1999; 3: 451-453.
33. World Health Organization. TB Treatment Observer, March 24, 1997.
34. Farmer P F, Bayona J, Becerra M, et al. The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2: 864-876.
35. Becerra M C, Bayona J, Freeman J, Kim J Y, Farmer P E. Redefining MDR-TB transmission 'hot spots'. Submitted for publication, 1999.
36. Farmer P E, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing 'DOTS-plus'. Brit Med J 1998; 317: 671-674.